Skip to content
Recall Observatory FDA recall evidence

Drug product

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

D-0511-2017

February 17, 2017

Class III

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 76513
Status
Terminated
Classification
Class III
Quantity
25,916 cartons
Official record key
drug-enforcement:D-0511-2017

Official wording

Reason: Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.

Code information: Lot # 34025762A, Exp 06/17

Distribution pattern: Nationwide in the United States and Puerto Rico

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    out of specification